Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

1478800

USP

Orlistat

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

(−)-Tetrahydrolipstatin, N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester, Ro-18-0647

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C29H53NO5
Numéro CAS:
96829-58-2
Poids moléculaire :
495.73
Numéro MDL:
MFCD05662360
Code UNSPSC :
41116107
ID de substance PubChem :
329750618
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

orlistat

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O

InChI

1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1

Clé InChI

AHLBNYSZXLDEJQ-FWEHEUNISA-N

Informations sur le gène

human ... LIPF(8513) , PNLIP(5406)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Orlistat USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Actions biochimiques/physiologiques

Orlistat, used in obesity research, is a pancreatic lipase inhibitor that acts locally in the gastrointestinal tract to inhibit lipase.

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Solution is not completely clear, small particles may remain floating.
Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1478833

Orlistat Related Compound C, United States Pharmacopeia (USP) Reference Standard

1478811

Orlistat Related Compound A, United States Pharmacopeia (USP) Reference Standard

1478844

Orlistat Related Compound D, United States Pharmacopeia (USP) Reference Standard

1478855

Orlistat Related Compound E, United States Pharmacopeia (USP) Reference Standard

1478822

Orlistat Related Compound B, United States Pharmacopeia (USP) Reference Standard

1680685

Tributyl phosphine oxide, United States Pharmacopeia (USP) Reference Standard

PHR2544

Orlistat Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2543

Orlistat Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

György Paragh et al.
Orvosi hetilap, 146(11), 493-498 (2005-04-09)
The overweight and obesity represent severe problems for the health management system of developed countries. In the evolution of obesity, beside genetic background, the environmental factors also play important roles. In the daily routine, the majority of obese patients need
Walmir Coutinho
Arquivos brasileiros de endocrinologia e metabologia, 53(2), 262-270 (2009-05-26)
Ancillary therapies for weight management, consisting mainly of diet and exercise programs that incorporate variable levels of lifestyle modification techniques, are frequently ineffective to achieve clinically meaningful weight loss and maintenance. Although pharmacological treatment of obesity is widely used in
James W Anderson
Expert opinion on pharmacotherapy, 8(11), 1733-1742 (2007-08-10)
Orlistat, in the 60-mg over-the-counter dose, was recently approved by the FDA. This lipase inhibitor blocks absorption of ~25% of ingested fat and has ~85% of the efficacy of the 120-mg dose for weight loss. Over 16 weeks weight loss
Sheridan Henness et al.
Drugs, 66(12), 1625-1656 (2006-09-08)
Orlistat (Xenical) is a reversible inhibitor of gastric and pancreatic lipases. In conjunction with a hypocaloric diet and moderate exercise, orlistat is an effective drug for use in the management of obesity in adults with or without comorbidities. Recent data
Juliet M Mancino
Current diabetes reports, 6(5), 389-394 (2006-11-02)
Orlistat, a pancreatic lipase inhibitor, was approved by the US Food and Drug Administration (FDA) in the spring of 1999 as an adjunct to lifestyle intervention for weight loss. This paper seeks to examine current issues regarding orlistat use in
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique